Cannabis Law and Access in Bulgaria

Bulgaria's cannabis framework is stricter than most people expect from an EU member state

Forty-three countries have now introduced some form of regulated cannabis access. Bulgaria is not one of them, at least not in any meaningful clinical or recreational sense. Read Bulgaria's Narcotics Control Act alongside the relevant EU directives and the short version is this: Bulgarian cannabis law is one of the more conservative frameworks on the continent, with a few nuances worth understanding if you're researching how European schedules compare.

For Australian readers, it's worth stating upfront that none of this is Australian law. Australia has its own scheduling regime under the Poisons Standard (SUSMP), its own Special Access Scheme, and its own Authorised Prescriber pathway. Bulgaria's framework is covered here purely for comparative and educational purposes, and nothing below is a suggestion to use, source or possess any substance.

A comparison like this only works if you keep the two systems apart in your head. The same word, "schedule", can mean quite different things in different countries, and the same plant can sit under very different legal labels depending on its THC content and its intended use.

How Bulgaria classifies cannabis under national law

Bulgaria's primary instrument is the Law on Narcotic Substances and Precursors (Закон за контрол върху наркотичните вещества и прекурсорите), first enacted in 1999 and amended several times since. Cannabis, meaning the plant, its resin, and extracts containing significant tetrahydrocannabinol (THC), is placed in Schedule I of the national narcotic substances list. That corresponds broadly to substances considered to have a high potential for misuse and no approved medical application under Bulgarian law.

Possession of cannabis for personal use is a criminal offence under Article 354a of the Penal Code. Penalties depend on quantity. Small amounts can attract fines or short custodial sentences; larger quantities, or any indication of supply intent, trigger more serious charges.

There is no formal "decriminalisation" provision in Bulgarian law of the kind seen in Portugal or the Netherlands. Prosecutorial discretion exists in practice, but there is no statutory floor beneath which possession becomes a civil rather than criminal matter. If the distinction between those terms is fuzzy, our explainer on the difference between decriminalisation and legalisation sets it out.

To put it plainly: Bulgaria has not moved. While Germany introduced its partial legalisation framework in 2024 and several other EU member states have broadened access, Bulgaria remains firmly at the restrictive end of the spectrum.

Medical cannabis: the legal gap that quietly exists

Here's where it gets a little more interesting. Bulgaria technically permits the import and dispensing of pharmaceutical-grade cannabis products, but the pathway is narrow and the infrastructure is thin.

In 2016, the Council of Ministers amended the Narcotics Control Act to allow authorised pharmacies to dispense cannabis-based medicines that have received marketing authorisation in an EU member state. This was primarily a mechanism to allow access to products approved elsewhere in the EU under Regulation (EC) No 726/2004, which governs centralised marketing authorisation through the European Medicines Agency. The logic is a familiar one in medicines regulation: rather than build a domestic approval system for every product, a country recognises an approval that another competent authority has already granted.

In practice, this means a Bulgarian patient can, in principle, access a cannabis-derived pharmaceutical product if a physician prescribes it, the product holds valid EU marketing authorisation, and a licensed pharmacy has arranged import. Each of those three conditions is a separate hurdle, and a failure at any one stops the chain.

The process is not straightforward. There is no domestic cultivation for pharmaceutical purposes operating at commercial scale, no national reimbursement scheme for cannabis-based medicines, and the prescribing culture is cautious. Physicians must work within the bounds of Bulgarian medical regulation, which does not have an equivalent to Australia's Schedule 8 Controlled Drug prescribing framework for cannabis. For readers who want to see how Australia handles unapproved products, the pages on the Special Access Scheme in Australia describe that separate system.

I'd argue this gap, legal in theory and largely inaccessible in practice, is the defining feature of Bulgaria's current position. The law permits access but the system doesn't really support it. That's not unusual in Eastern Europe, but it's worth naming directly.

Hemp, CBD, and where the lines are drawn

Industrial hemp is a different story. Bulgaria has a reasonably active hemp cultivation sector, operating under EU rules that require registered varieties of Cannabis sativa with THC content at or below 0.2% (the EU threshold at time of writing, though the Commission has discussed moving this to 0.3% to align with other markets).

Licensed cultivation is permitted for fibre, seed, and related agricultural purposes under oversight from the Bulgarian Food Safety Agency. Farmers must use varieties on the EU Common Catalogue of Varieties and comply with inspection requirements. The threshold is applied to the plant and its variety, not to a finished consumer product, which is a common point of confusion.

Cannabidiol (CBD) products sit in a genuinely uncertain space. The European Court of Justice's 2020 ruling in Kanavape (Case C-663/18) established that CBD derived from the whole cannabis plant, not just the seed and fibre, cannot be treated as a narcotic under EU law where it contains no psychoactive THC. Bulgaria, as an EU member state, is bound by that ruling.

But national-level implementation has been inconsistent across member states, and Bulgaria has not enacted clear standalone regulation for CBD consumer products. The practical result is a grey market: CBD products are sold in shops in Sofia and other cities, but without a definitive regulatory classification they exist in a legal grey zone that could, theoretically, be revisited by authorities at any time.

For anyone interested in how cannabinoid chemistry underpins these distinctions, and why regulators treat THC and CBD so differently, our glossary entries on the endocannabinoid system, CB1 receptor, and CB2 receptor explain the pharmacological basis for these classifications in plain language.

Bulgarian cannabis law in the EU context

Bulgaria joined the EU in 2007 and is therefore subject to EU-level frameworks on narcotic substances, including UN conventions to which the EU and its member states are party, specifically the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. These conventions shape the floor below which member state law cannot easily go without triggering diplomatic complexity, though several states have found creative ways to reform within those constraints.

The EU does not have a single harmonised cannabis policy. Member states retain sovereignty over criminal law in this space. What the EU does harmonise is the movement of controlled substances, pharmaceutical market authorisation, and hemp agriculture.

Bulgaria's participation in these frameworks is unremarkable. It complies with the EU's hemp THC thresholds and recognises centrally authorised medicines, but it has not been an active participant in the reform conversations happening in Berlin, Amsterdam, or Brussels. The legal framework for industrial production exists. Whether broader reform follows the Western European trajectory is genuinely uncertain.

What this means for understanding global reform patterns

Bulgaria is a useful data point precisely because it hasn't moved. Comparative legal research requires examples of jurisdictions that have maintained stricter frameworks alongside those liberalising, so you can actually measure what changes and what doesn't when reform happens.

The split between hemp-permissive and cannabis-restrictive is not unique to Bulgaria, it's actually the norm across most of Central and Eastern Europe. What's interesting is that EU agricultural policy (which supports hemp as a crop) and EU criminal justice norms (which remain largely silent on cannabis prohibition) have produced this consistent pattern: grow the plant for fibre, prosecute for the flower.

From a chemistry standpoint, the distinction hinges almost entirely on THC concentration and the regulatory meaning assigned to it. Minor cannabinoids like cannabigerol (CBG) and the various terpenes present in the plant, including common ones like beta-caryophyllene and myrcene, are not individually scheduled in Bulgarian law. They fall in or out of regulation based on what plant material they're derived from and whether that material is classified as hemp or cannabis.

That's a crude proxy for a genuinely complex phytochemistry, but it's how most national frameworks, including Australia's, have approached the problem. The science and the law are not well aligned here, and I don't think that's likely to change quickly in Bulgaria's case.

Common mistakes when comparing national cannabis laws

The first mistake is treating "legal" as a single state. A country can allow hemp farming, permit imported medicines, tolerate a grey consumer market and still criminalise personal possession, all at once. Bulgaria is a good illustration, because each of those layers sits under a different body of law.

The second is assuming that a headline about reform describes the whole system. Germany's 2024 changes, for example, say little about how a pharmacy in another member state handles an imported medicine. Always check which layer a news story is talking about: criminal law, medicines regulation, or agriculture.

The third is reading Australian concepts into foreign law. Terms such as Schedule 8, Authorised Prescriber and Special Access Scheme have specific meanings under the TGA framework, and the Therapeutic Goods Administration remains the authoritative source for how they operate here. A foreign statute that uses similar words may be doing something quite different.

Finally, check the date and the source of any legal summary, including this one. Statutes are amended, court rulings are applied unevenly, and thresholds such as the hemp THC limit are periodically discussed. The primary texts listed below are the right place to verify the current position.

Sources

• Bulgaria Country Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Case C-663/18 (Kanavape ruling), Court of Justice of the European Union
• International Drug Control Conventions; United Nations Office on Drugs and Crime (UNODC)
• Medical Use of Cannabis in the EU, EMCDDA

Marcus Hale, Regulatory researcher, TGA & access law